UNSPSC 51343502: Cidofovir

This classification denotes an antiviral agent with the molecular formula C8H14N3O6P.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, JIL713Q00N chemically known as phosphonic acid, ((2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy)methyl)-, dihydrate, (s)- but generally known as cidofovir, which bears US NIH Compound Identifier 60613. European Medicines Agency schedules Cidofovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06257MIG.

UNSPSC 51343502 Cidofovir is a Commodity code that does not reflect the actual procurement activity posted under it in recent state and local solicitations. The code nominally names a specific antiviral pharmaceutical (cidofovir), but the recent opportunities posted under this code span naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products, medical and first aid supplies for emergency response, and exploratory pharmacy benefit program contracting — none of which are cidofovir. The issuing bodies include Seminole County, Florida; the City of Tampa; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), representing county health departments, municipal fire rescue divisions, state health agencies, and regional cooperative purchasing vehicles.

Geographically, recent activity under this code appears in Florida, Texas, and Minnesota, with MMCAP's scope extending to Oregon and multiple participating jurisdictions. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline; the City of Tampa's IFB 26P00145 (posted March 25, 2026) for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division with a March 13, 2026 due date and an estimated contract value of $700,000.00; and MMCAP's RFP S1070000015802 (posted January 20, 2026) for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline. The code shows activity but demonstrates significant misalignment between its nominal scope and the pharmaceutical, medical, and emergency-response products actually being procured under it. Vendors pursuing opportunities in this taxonomy should verify alignment between the posted UNSPSC classification and actual procurement scope before bid preparation.